Inogen, Inc. — Form 10-Q summary
Reporting period: Quarter and nine months ended September 30, 2016; filed November 3, 2016. Inogen develops, manufactures, sells, and rents portable oxygen concentrators. Unless otherwise noted, financial amounts below are in U.S. dollars and millions; the filing reports financial statements in thousands.
Financial performance
| Metric | Q3 2016 | Q3 2015 | Nine months 2016 | Nine months 2015 |
|---|---|---|---|---|
| Total revenue | $54.4 | $40.8 | $152.0 | $118.6 |
| Sales revenue | $47.2 | $29.2 | $125.6 | $84.7 |
| Rental revenue | $7.2 | $11.5 | $26.4 | $33.9 |
| Gross profit | $25.1 | $19.4 | $72.6 | $56.2 |
| Gross margin | 46.2% | 47.5% | 47.8% | 47.4% |
| Income from operations | $5.4 | $3.7 | $16.7 | $11.6 |
| Net income | $3.5 | $2.7 | $11.0 | $7.7 |
| Diluted EPS | $0.16 | $0.13 | $0.52 | $0.37 |
- Growth and mix: Q3 revenue rose 33.5%; nine-month revenue rose 28.2%. Sales growth reflected higher domestic and international business-to-business sales and direct-to-consumer demand. Systems sold increased to approximately 26,600 in Q3 from 14,700, and to 68,700 for nine months from 42,100.
- Margins: Sales gross margin improved to 48.6% in Q3 and 49.2% for nine months, attributed mainly to lower unit costs on upgraded G3 and new G4 products. Rental gross margin fell to 30.7% in Q3 from 53.5%, and to 41.2% for nine months from 53.2%, as reimbursement reductions and rental revenue adjustments outweighed lower service costs.
- Cash flow: Nine-month operating cash flow was $25.9 million, versus $25.6 million. Investing used $11.4 million, compared with $28.8 million, largely reflecting marketable-security purchases and capital spending; financing provided $5.4 million, chiefly from option exercises and employee stock purchases. Cash and cash equivalents increased to $86.0 million from $66.1 million at year-end 2015.
- Liquidity and debt: Marketable securities were $22.3 million; net working capital was $127.8 million. The company had $15.0 million available under its revolving credit facility and no revolver borrowings. Remaining patent-purchase debt was $80,000, due in the final quarter of 2016. Total liabilities were $38.7 million.
- Balance-sheet movements: Net accounts receivable increased to $29.7 million from $19.9 million and inventory to $16.5 million from $8.6 million. Management attributed cash use in working capital to growth, extended business-to-business payment terms, and rental-receivable collection timing.
Material changes and management outlook
- Rental revenue declined 37.2% in Q3 and 22.0% for the first nine months, reflecting Medicare rate cuts, lower private-payor rates, and increased rental revenue adjustments. Management expected rental revenue to decline approximately 25%–30% in 2016 versus 2015, and to decline again in 2017. Rental gross margin was also expected to weaken in Q4 2016 and full-year 2017.
- Management identified sales growth as a priority and reported launching the Inogen One G4 in May 2016. It planned a broader domestic business-to-business launch in Q4 2016 and an international business-to-business launch in the first half of 2017, subject to regulatory and reimbursement approvals. Management also expected research and development, sales and marketing, and general and administrative expenses to rise in future periods.
- Management said available cash, securities, credit capacity, and expected operating cash generation should cover projected operating and investing needs for at least 12 months. This is a forward-looking assessment, not a guarantee.
- Medicare reimbursement is a significant exposure for rentals: Medicare service programs generated 71.6% of nine-month rental revenue, while Medicare-related revenue represented 12.4% of total revenue. Competitive bidding and nationalized regional pricing reduced rates; management cited further pressure from future bidding, payer responses, capped rentals, and claim adjustments.
Risks, contingencies, and unusual items
- Litigation: Inogen settled its patent dispute with Inova Labs in June 2016 and recorded settlement-related gains, including $72,000 in Q3. A California wage-and-hour class settlement had approximately $980,000 accrued, pending final court approval. Inogen is contesting patent and trade-secret claims by Separation Design Group and a patent-infringement suit filed by CAIRE in September 2016; claimed damages are unspecified.
- Other exposures: The company reported approximately $40.2 million of outstanding supplier purchase orders, generally not extending beyond 12 months, and dependence on a limited number of suppliers for key components. Three vendors represented 22.0%, 14.9%, and 7.9% of nine-month raw-material purchases.
- Receivables and estimates: Nine-month cash flow included $8.2 million of provisions for sales returns and doubtful accounts and $7.8 million of rental revenue adjustments. Allowance estimates, payer audits, reimbursement documentation, and collection timing may affect reported revenue and cash conversion.
- Other risks: The filing highlights regulation and reimbursement changes, product liability and warranty costs, competition, foreign-exchange exposure, manufacturing continuity, and intellectual-property disputes. Warranty liabilities were $3.4 million at September 30, 2016, compared with $2.0 million at year-end 2015.
Key facts for investors to verify
- Whether strong system-sales growth and improved sales margins can persist as the business shifts toward lower-margin business-to-business sales.
- How Medicare and private-payor rate reductions affect rental revenue, rental margins, patient additions, and the stated 2016–2017 rental outlook.
- Whether higher receivables and inventories convert into cash as expected; review collection trends, reserves, and customer concentration.
- Developments and potential financial impact of the SDGIP and CAIRE lawsuits, and final approval and payment of the labor settlement.
- Execution of G4 launches, product demand, supplier capacity, and the company’s ability to meet its $40.2 million of purchase commitments.
- Compliance with revolving-credit covenants and the company’s liquidity forecast; the filing reported covenant headroom at September 30, 2016.